drugset / Trial / NCT04288323
Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis
Phase 4
Completed
79 enrolled
University of California, San Diego
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · collabIcahn School of Medicine at Mount Sinai · collab
NaSingle-groupOpen-labelScreening
Summary
This study compares gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for Hepatocellular Carcinoma (HCC) screening and surveillance in subjects with liver cirrhosis.
Timeline
- Start
- 2018-04-27
- Primary completion
- 2025-12-16
- Completion
- 2025-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Gadoxetate Disodium | Diagnostic / imaging agent | — | — |